Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | APP | P05067 | 3/20 | 0.70 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.67 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138238 | 1.00 | MAPT (0.71) | MAPTNPC1RAB9AMEN1MAPK1 | |
| SCHEMBL634205 | 0.91 | NR1H4 (0.79) | MAPTNPC1RAB9AMEN1MAPK1 | |
| SCHEMBL634206 | 0.91 | NR1H4 (0.79) | MAPTNPC1RAB9AMEN1MAPK1 | |
| SCHEMBL661643 | 0.90 | NR1H4 (0.66) | MAPTNPC1RAB9AMEN1MAPK1 | |
| SCHEMBL661644 | 0.90 | NR1H4 (0.66) | MAPTNPC1RAB9AMEN1MAPK1 | |
| SCHEMBL4449583 | 0.89 | MAPT (0.77) | MAPTNPC1RAB9AMEN1MAPK1 | |
| SCHEMBL4449587 | 0.89 | MAPT (0.77) | MAPTNPC1RAB9AMEN1MAPK1 | |
| SCHEMBL331296 | 0.89 | NR1H4 (0.83) | MAPTNPC1RAB9AMEN1MAPK1 | |
| SCHEMBL633204 | 0.89 | NR1H4 (0.83) | MAPTNPC1RAB9AMEN1MAPK1 | |
| SCHEMBL5084423 | 0.85 | MAOB (0.80) | MAPTABCG2NR1H4ALOX5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-10 | — | — | US | disclosed |
| US-9763961-B2 | Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use | CITY OF HOPE (US) | 2017-09-19 | — | — | US | disclosed |
| US-9763961-B2 | Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use | CITY OF HOPE (US) | 2017-09-19 | — | — | US | disclosed |
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
| US-20100279987-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | SALIOU CLAUDE | 2010-11-04 | — | — | US | disclosed |
| US-20100279987-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | SALIOU CLAUDE | 2010-11-04 | — | — | US | disclosed |
| US-7781410-B2 | Compositions containing chalcones and use thereof | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781410-B2 | Compositions containing chalcones and use thereof | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20090124688-A1 | Prostaglandin reductase inhibitors | ABGENOMICS CORPORATION (TW) | 2009-05-14 | — | — | US | disclosed |
| US-20090124688-A1 | Prostaglandin reductase inhibitors | ABGENOMICS CORPORATION (TW) | 2009-05-14 | — | — | US | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20080032938-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | JOHNSON & JOHNSON CONSUMER INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080032938-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | JOHNSON & JOHNSON CONSUMER INC. | 2008-02-07 | — | — | US | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007082178-A2 | PROSTAGLANDIN REDUCTASE INHIBITORS | ABGENOMICS CORPORATION (TW) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | MAPT 4566/4885NPC1 362/4885RAB9A 3126/4885 |
| US-20080032938-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | CYP17A1, HSD17B7, CUTA | MAPT 2236/4885NPC1 344/4885RAB9A 4564/4885 |
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | ESRRG, GPER1, ESR2 | MAPT 4210/4885NPC1 4155/4885RAB9A 3745/4885 |
| US-20100279987-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | CYP17A1, HSD17B7, CUTA | MAPT 2236/4885NPC1 344/4885RAB9A 4564/4885 |
| US-20090124688-A1 | Prostaglandin reductase inhibitors | PTGIR, PTGDR, PTGDR2 | MAPT 4718/4885NPC1 1055/4885RAB9A 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.